Accessibility Menu
Scancell Plc logo

Scancell Plc(LSE) SCLP

Market Cap£116.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)+222%
5 Year-54%
1 Year-9%
1 Month-28%
£0.10
+0.00%
+0.00Today
Scancell Plc last closing stock price
MetricPriceDate
Last closeGBX 9.602026-08-13
Scancell Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.05%GBX 9.502026-08-06
1 month-27.55%GBX 13.252026-07-14
3 month-57.8%GBX 22.752026-05-15
Year to date-3.03%GBX 9.902025-12-31
1 year-8.57%GBX 10.502025-08-13
3 year-16.52%GBX 11.502023-08-14
5 year-53.71%GBX 20.742021-08-13
Since inception+221.63%GBX 0.032009-06-29

Scancell Plc Financials at a Glance

Market Cap

£116.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£4.71M

Net Income (TTM)

-£21.33M

EPS (TTM)

-£0.01

P/E Ratio

-18.11

Dividend

£0.00

Beta (Volatility)

0.18 (Low)

Price

£0.10

Volume

132,947

Open

£0.10

Previous Close

£0.10

Daily Range

£0.10 - £0.10

52-Week Range

£0.08 - £0.30

Estimated Earnings Date

Oct 23, 2026

SCLP News

12-Bagger Scancell Holdings Offers "Positive" Results

Sam RobsonJan 31, 2013

3 Shares the FTSE 100 Beat Today

Alan OscroftJan 31, 2013

3 Shares the FTSE 100 Should Beat Today

Alan OscroftJan 29, 2013

3 Shares That Beat the FTSE Today

Alan OscroftDec 12, 2012

3 Shares Set to Beat the FTSE Today

Alan OscroftDec 6, 2012

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scancell Plc

Scancell Holdings plc is a clinical-stage biopharmaceutical firm dedicated to developing innovative vaccine and antibody treatments. The company focuses on addressing significant unmet medical needs in cancer and infectious diseases through its advanced pipeline of therapeutic candidates.

Products and Services
  • SCIB1: In Phase II trials for metastatic melanoma
  • SCIB2: Targeting non-small cell lung cancer
  • Modi-1: Undergoing Phase I/II studies for multiple cancer types
Growth Outlook
  • Pipeline includes multiple candidates with promising clinical data
  • Recent partnerships enhance research capabilities and market reach
  • Focus on expanding therapeutic applications for existing products
Financial Highlights
  • Recent quarterly revenue of £0, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) net income of -£25.5 million, indicating significant R&D expenses
  • Cash reserves of £8.57 million as of the latest quarter, supporting ongoing operations
Scancell Holdings plc is positioned in the biotechnology sector, focusing on innovative solutions for serious health challenges. The company's pipeline includes several candidates in various stages of clinical trials, showcasing its commitment to advancing cancer therapies. Despite recent financial challenges, including a net loss, the company maintains a robust cash position to support its research and development efforts. The strategic focus on partnerships and expanding therapeutic applications may provide avenues for future growth and market penetration. Investors may find the company's innovative approach and potential for breakthroughs in treatment appealing as it navigates the complexities of the biopharmaceutical landscape.
AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Philip John L'Huillier, PhD, MBA

Website

www.scancell.co.uk

Headquarters

Oxford, OX OX4 4GD, GB

SCLP Financials

Key Financial Metrics (TTM)

Gross Margin

78.45%

Operating Margin

-283.34%

Net Income Margin

-116.98%

Return on Equity

90.29%

Return on Capital

-120.66%

Return on Assets

-35.84%

Earnings Yield

-5.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£116.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.21B

Volume

132.95K

Avg. Volume

3.67M

Financials (TTM)

Gross Profit

£2.69M

Operating Income

-£34.04M

EBITDA

-£22.56M

Operating Cash Flow

-£22.43M

Capital Expenditure

-£375.00K

Free Cash Flow

-£22.61M

Cash & ST Invst.

£8.57M

Total Debt

£16.18M

Scancell Plc Performance Analysis

Scancell Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-04-30GBP 0N/A
20232023-04-30GBP 5,271,000N/A
20242024-04-30GBP 0N/A
20252025-04-30GBP 4,711,000N/A
Scancell Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-04-30N/A
Q22024-10-31N/A
Q42025-04-30N/A
Q22025-10-31-100.0%
Scancell Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-04-30GBP -0.01N/A
20232023-04-30GBP -0.01160.7%
20242024-04-30GBP -0.01-53.4%
20252025-04-30GBP -0.0185.3%
Scancell Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-04-30-19.4%
Q22024-10-31-262.2%
Q42025-04-30101.5%
Q22025-10-31-3300.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£377.00K

+13.1%

Gross Margin

0.00%

N/A

Market Cap

£116.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£1.94M

N/A

Employees

60

N/A

Net Income

-£5.74M

-125.4%

EBITDA

-£5.45M

-105.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£8.57M

-34.4%

Total Debt

£16.18M

-25.3%

Accounts Receivable

£4.69M

+886.1%

Inventory

£0.00

N/A

Long Term Debt

£0.00

-100.0%

Short Term Debt

£16.18M

+647.1%

Return on Assets

-35.84%

N/A

Return on Invested Capital

1.59%

N/A

Free Cash Flow

-£7.08M

-6.2%

Operating Cash Flow

-£7.08M

-6.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EKF.LEKF Diagnostics Holdings plc
£0.26+0.77%
BVXP.LBioventix PLC
£14.92-0.53%
HVO.LhVIVO plc
£0.07+1.49%
STX.LShield Therapeutics plc
£0.04+0.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%
INTCIntel
$100.95+0.03%
NOKNokia
$10.32+0.09%

Questions About SCLP

What is the current price of Scancell Plc?

Scancell Plc is trading at £0.10 per share.

What is the 52-week range for Scancell Plc?

Over the past 52 weeks, Scancell Plc has traded between £0.08 and £0.30.

How much debt does Scancell Plc have?

As of the most recent reporting period, Scancell Plc reported total debt of £16.27M.

How much cash does Scancell Plc have on hand?

Scancell Plc reported £16.89M in cash and cash equivalents in its most recent financial results.

What is Scancell Plc’s dividend yield?

Scancell Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services